Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Schering-Plough_Corporation
|
| gptkbp:activities |
inhibits cholesterol absorption
inhibits HMG-Co A reductase |
| gptkbp:appointed_by |
oral route
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:associated_with |
improved lipid profile
reduced cardiovascular risk |
| gptkbp:brand |
gptkb:Vytorin
|
| gptkbp:clinical_trial |
Phase IV
hyperlipidemia mixed dyslipidemia increased HDL cholesterol reduced LDL cholesterol reduced triglycerides |
| gptkbp:contains |
gptkb:ezetimibe
gptkb:simvastatin |
| gptkbp:contraindication |
liver disease
pregnancy allergy to components |
| gptkbp:discontinued |
some markets
|
| gptkbp:dosage_form |
oral
|
| gptkbp:form |
gptkb:tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Vytorin
|
| gptkbp:interacts_with |
gptkb:HIV_protease_inhibitors
certain antibiotics antifungal medications |
| gptkbp:invention |
gptkb:2017
|
| gptkbp:is_available_in |
various strengths
|
| gptkbp:is_available_on |
gptkb:brand
generic version |
| gptkbp:is_used_for |
lowering cholesterol
|
| gptkbp:manufacturer |
gptkb:Merck_&_Co.
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:2004 gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:previous_name |
ezetimibe/simvastatin
|
| gptkbp:related_to |
statins
cholesterol absorption inhibitors |
| gptkbp:requires |
prescription only
|
| gptkbp:scholarships |
monitor liver function
report unexplained muscle pain avoid grapefruit juice |
| gptkbp:side_effect |
muscle pain
allergic reactions liver damage cognitive impairment gastrointestinal issues diabetes risk |
| gptkbp:storage |
room temperature
protected from moisture away from light |
| gptkbp:successor |
generic ezetimibe/simvastatin
|